Publications (18) Javier Gonzalez Vaz publications

filter_list

2024

  1. CD137 (4-1BB) and T-Lymphocyte Exhaustion

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 3971-3973

  2. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  3. Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting Glypican 3 effectively control human hepatocellular carcinoma in mice

    Hepatology

2023

  1. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  2. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

    Cancer discovery, Vol. 13, Núm. 3, pp. 552-569

  3. Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity

    Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198

  4. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 668-682

  5. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  6. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

  7. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

  2. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

2021

  1. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

  2. Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils

    European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280

  3. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

  4. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

2020

  1. Inflammation and immunity in ovarian cancer

    European Journal of Cancer, Supplement, Vol. 15, pp. 56-66

  2. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

    ESMO open, Vol. 4, pp. e000733